Skip to main content

Table 1 Baseline patient demographics and disease characteristics (safety population)

From: Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

  Placebo (n = 9) Namilumab 150 mg (n = 8) Namilumab 300 mg (n = 7) Total (N = 24)
Gender, n (%)
 Female 6 (67) 5 (63) 6 (86) 17 (71)
 Male 3 (33) 3 (38) 1 (14) 7 (29)
Race, n (%)
 White 9 (100) 7 (88) 7 (100) 23 (96)
 Black 0 1 (13) 0 1 (4)
Age, yearsa 56 (29–65) 59 (43–65) 59 (36–75) 59 (29–75)
BMI, kg/m2b 27.37 (2.246) 24.69 (2.471) 28.30 (1.778) 26.75 (2.607)
Disease duration, years 3.3 (0.9–10.9) 4.9 (1.7–19.0) 5.2 (3.0–9.3) 4.4 (0.9–19.0)
DAS28-ESRb 4.8 (0.41) 4.9 (0.35) 4.4 (0.59) 4.7 (0.48)
DAS28-CRPb 4.4 (0.82) 4.2 (0.52) 4.0 (0.62) 4.2 (0.65)
ESR, mm/hourb 31 (11.91) 28 (5.56) 23 (8.06) 28 (9.31)
CRP, mg/literb 21 (22.64) 8 (6.75) 12 (10.44) 13 (15.43)
TJCb (0–68) 8.7 (5.45) 9.1 (6.92) 9.6 (4.69) 9.1 (5.55)
SJCb (0–66) 5.0 (5.41) 4.3 (2.38) 6.1 (5.30) 5.1 (4.45)
  1. The eligibility criteria allowed patients with previous biological therapy into the study, however, all of patients enrolled into the PRIORA study were biologic naive
  2. BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SD standard deviation, SJC swollen joint count, TJC tender joint count
  3. aMedian (range); bmean (SD)